Name: Pearce IP
Address: Level 5/20 Bond St, Sydney, NSW, 2000, AU
Telephone: (02) 9023 9988
Price range: $$

Read our latest updates & insights

Stay informed about important legal and industry news with our blogs and weekly BioBlast® updates.

CHMP gives positive approval for Boehringer Ingelheim's AmAb

By Bioblast Editor | Sep 15, 2017

Read more

BI receives positive CHMP opinon on Cyltezo®, biosimilar to adalimumab. Approval is expected in Q4/17.
First wave of patent reform in AU: consultation period ends 17 Nov 2017

By Naomi Pearce | Sep 14, 2017

Read more

IP Australia is inviting submissions by 17 November 2017 on the first wave of IP reform initiatives arising from the Government’s response to the Productivity Commission Repor...
Amgen/Allergan's bevacizumab Mvasti® approved in the US

By Bioblast Editor | Sep 14, 2017

Read more

Amgen/Allergan’s bevacizumab biosimilar (Mvasti®) (bevacizumab-awwb) approved in the US for colorectal, lung, brain, kidney and cervical cancer. Read more
Sandoz announces 51 week results for AmAb biosimilar

By Bioblast Editor | Sep 14, 2017

Read more

Sandoz announces at the EADV results from 51 week clinical study confirming that Sandoz’s biosimilar adalimumab matches Humira® in safety and efficacy profile.
Medicines for Europe Issues 2017 Biosimilar Market Review

By Naomi Pearce | Sep 13, 2017

Read more

Eleven years after the launch of the first biosimilar product in EU, we are now in a position to calibrate our biosimilar market expectations with market experience, rather than ext...
Lupin secures external funding for etanercept program

By Bioblast Editor | Sep 13, 2017

Read more

Lupin secures external funding for its etanercept biosimilars program.
Sandoz's application for rituximab accepted

By Bioblast Editor | Sep 12, 2017

Read more

FDA accepts Sandoz’s s351(k) application for rituximab.
BLA for biosimilar filgratism accepted

By Bioblast Editor | Sep 11, 2017

Read more

FDA accepts Adello Biologic’s BLA for biosimilar filgrastim.
Pfizer Phase III study for TmAb candidate announced

By Bioblast Editor | Sep 09, 2017

Read more

Pfizer announces positive findings in pivotal Phase III study for TmAb candidate PF-05280014 at ESMO 17.
Phase III data on Amgen/Allergan biosimilar trastuzumab released

By Bioblast Editor | Sep 09, 2017

Read more

Amgen/Allergan present Phase III data on biosimilar trastuzumab ABP 980 at ESMO 2017.